FY2024 · ended Jun 30, 2024 · Revenue $2.29M, -32.7% YoY · Filed Sep 30, 2024
Renalytix plc (RNLXY) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2024, which ended Jun 30, 2024, it reported revenue of $2.3 million and a net loss of $33.5 million. As of Sep 30, 2024 it held $909,000 in cash and investments and $11,500 in total debt.
Revenue (TTM)
$2.35M
Net income (TTM)
$-28.03M
Operating cash flow (TTM)
$-24.44M
Free cash flow
$-34.09M
+26.7% vs prior year
EPS (TTM)
$-0.25
Dividend per share
None
Shares outstanding
165.93M
+74.6% vs prior year
Net cash
$897,500
as of Sep 30, 2024
Operating margin
-1054.9%
FY 2025
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- RNLXY (OTC), RENXF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1811115
- Former names
- Renalytix AI plc (until Jun 25, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
FY 2021 Jun 30, 2021 |
FY 2020 Jun 30, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.3M | $3.4M | $3.0M | $1.5M | — |
| Operating income | -$29.6M | -$42.2M | -$53.2M | -$31.9M | -$10.3M |
| Net income | -$33.5M | -$45.6M | -$45.3M | -$35.3M | -$9.8M |
| Diluted EPS | -$0.31 | -$0.55 | -$0.67 | — | — |
| Operating cash flow | -$30.1M | -$34.1M | -$45.9M | -$28.4M | -$9.5M |
| Free cash flow | — | -$34.1M | -$46.5M | -$29.2M | -$10.3M |
| Total assets | $8.0M | $30.6M | $50.1M | $78.6M | $20.9M |
| Total liabilities | $15.8M | $23.7M | $19.5M | $7.1M | $5.0M |
| Stockholders' equity | -$7.9M | $7.0M | $30.6M | $71.5M | $15.9M |
| Cash and investments | $4.7M | $24.7M | $41.3M | $65.1M | $14.3M |
| Total debt | $45,000 | $171,000 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Jan 16, 2025 | Jan 16, 2025 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Dec 20, 2024 | Dec 19, 2024 |
| 8-K/A |
Amended current report
Material agreement, New debt
|
Nov 19, 2024 | Sep 26, 2024 |
| 10-Q | Quarterly report | Nov 19, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Regulation FD disclosure
|
Nov 6, 2024 | Oct 31, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Results of operations, New debt, Listing notice, Unregistered share sale, Other events
|
Oct 1, 2024 | Sep 26, 2024 |
All 233 Renalytix plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.